Patents Assigned to Pacific Northwest Research Institute
  • Patent number: 11446271
    Abstract: Embodiments provided herein include methods, compositions, and uses of aromatic alcohols to increase the potency of antifungal agents.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: September 20, 2022
    Assignee: PACIFIC NORTHWEST RESEARCH INSTITUTE
    Inventors: Catherine Ludlow, Aimee Dudley, Zhihao Tan
  • Patent number: 10751317
    Abstract: Embodiments provided herein include methods, compositions, and uses of aromatic alcohols to increase the potency of antifungal agents.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: August 25, 2020
    Assignee: PACIFIC NORTHWEST RESEARCH INSTITUTE
    Inventors: Catherine Ludlow, Aimee M. Dudley, Zhihao Tan
  • Publication number: 20160033512
    Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.
    Type: Application
    Filed: July 27, 2015
    Publication date: February 4, 2016
    Applicant: PACIFIC NORTHWEST RESEARCH INSTITUTE
    Inventors: Ingegerd Hellstrom, Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
  • Patent number: 9090712
    Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: July 28, 2015
    Assignee: PACIFIC NORTHWEST RESEARCH INSTITUTE
    Inventors: Ingegerd Hellstrom, Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
  • Patent number: 8268561
    Abstract: A method of genetically screening large numbers of individuals to identify those individuals requiring follow-up testing for active Type I diabetes (T1D) is provided. The method includes obtaining a nucleic-acid containing biological sample from each individual and testing for the presence of specific combinations of HLA II alleles in the sample.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: September 18, 2012
    Assignee: Pacific Northwest Research Institute
    Inventors: William Hagopian, Hui Peng
  • Publication number: 20110104675
    Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages.
    Type: Application
    Filed: May 17, 2010
    Publication date: May 5, 2011
    Applicant: Pacific Northwest Research Institute
    Inventors: Nathalie Scholler, Ingegerd Hellstrom, Karl Erik Hellstrom
  • Publication number: 20100047818
    Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.
    Type: Application
    Filed: August 6, 2009
    Publication date: February 25, 2010
    Applicant: PACIFIC NORTHWEST RESEARCH INSTITUTE
    Inventors: Ingegerd Hellstrom, Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
  • Publication number: 20090311697
    Abstract: A method of genetically screening large numbers of individuals to identify those individuals requiring follow-up testing for active Type I diabetes (T1D) is provided. The method includes obtaining a nucleic-acid containing biological sample from each individual and testing for the presence of specific combinations of HLA II alleles in the sample.
    Type: Application
    Filed: April 8, 2009
    Publication date: December 17, 2009
    Applicant: PACIFIC NORTHWEST RESEARCH INSTITUTE
    Inventors: William HAGOPIAN, Hui PENG
  • Publication number: 20090104684
    Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.
    Type: Application
    Filed: August 8, 2007
    Publication date: April 23, 2009
    Applicants: Pacific Northwest Research Institute, University of Washington
    Inventors: Michel Schummer, INGEGERD HELLSTROM, Karl Erik Hellstrom, JEFFREY A. LEDBETTER, MARTHA HAYDEN-LEDBETTER
  • Patent number: 7270960
    Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.
    Type: Grant
    Filed: August 28, 2002
    Date of Patent: September 18, 2007
    Assignee: Pacific Northwest Research Institute
    Inventors: Ingegerd Hellstrom, Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
  • Publication number: 20040219161
    Abstract: The invention provides compositions and methods directed to cell surface receptor antigen specific vaccines. More specifically, vaccines are provided that induce or enhance host antibody titers specific for cell surface receptor antigens and that include recombinant expression constructs containing nucleic acids encoding a target cell surface receptor antigen and one or more immune response altering molecules, or the expressed products themselves.
    Type: Application
    Filed: January 20, 2004
    Publication date: November 4, 2004
    Applicant: Pacific Northwest Research Institute
    Inventors: Nathalie B. Scholler, Mary L. Disis, Ingegerd Hellstrom, Karl Erik Hellstrom
  • Patent number: 6770445
    Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: August 3, 2004
    Assignee: Pacific Northwest Research Institute
    Inventors: Nathalie B. Scholler, Ingegerd Hellstrom, Karl Erik Hellstrom
  • Publication number: 20040142396
    Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages.
    Type: Application
    Filed: February 13, 2004
    Publication date: July 22, 2004
    Applicant: Pacific Northwest Research Institute
    Inventors: Nathalie B. Scholler, Ingegerd Hellstrom, Karl Erik Hellstrom
  • Patent number: 6734172
    Abstract: The invention provides compositions and methods directed to cell surface receptor antigen specific vaccines. More specifically, vaccines are provided that induce or enhance host antibody titers specific for cell surface receptor antigens and that include recombinant expression constructs containing nucleic acids encoding a target cell surface receptor antigen and one or more immune response altering molecules, or the expressed products themselves.
    Type: Grant
    Filed: November 16, 1999
    Date of Patent: May 11, 2004
    Assignee: Pacific Northwest Research Institute
    Inventors: Nathalie B. Scholler, Mary L. Disis, Ingegerd Hellstrom, Karl Erik Hellstrom
  • Publication number: 20030108965
    Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.
    Type: Application
    Filed: August 28, 2002
    Publication date: June 12, 2003
    Applicant: Pacific Northwest Research Institute
    Inventors: Michel Schummer, Ingegerd Hellstrom, Karl Erik Hellstrom, Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
  • Patent number: 6214550
    Abstract: Methods of screening for a tumor or tumor progression to the metastatic state are disclosed. The screening methods are based on the characterization of DNA by principal components analysis of spectral data yielded by Fourier transform-infrared spectroscopy of DNA samples. The methods are applicable to a wide variety of DNA samples and cancer types. A model developed using multivariate normal distribution equations and discriminant analysis is particularly well suited for distinguishing primary cancerous tissue from metastatic cancerous tissue.
    Type: Grant
    Filed: June 25, 1998
    Date of Patent: April 10, 2001
    Assignee: Pacific Northwest Research Institute
    Inventor: Donald C. Malins